Gilead Sciences Correlations

GILD Stock  USD 108.22  0.58  0.53%   
The current 90-days correlation between Gilead Sciences and Caribou Biosciences is 0.39 (i.e., Weak diversification). The correlation of Gilead Sciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Gilead Sciences Correlation With Market

Very weak diversification

The correlation between Gilead Sciences and DJI is 0.5 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Gilead Sciences and DJI in the same portfolio, assuming nothing else is changed.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Moving together with Gilead Stock

  0.74PFE Pfizer IncPairCorr
  0.81CGEN CompugenPairCorr
  0.68FNMFO Federal National MortgagePairCorr
  0.71KB KB Financial Group Earnings Call This WeekPairCorr
  0.74SHG Shinhan Financial Earnings Call This WeekPairCorr
  0.7WF Woori Financial Group Earnings Call This WeekPairCorr
  0.69CSCO Cisco SystemsPairCorr
  0.65IBM International Business Earnings Call This WeekPairCorr
  0.61AA Alcoa CorpPairCorr
  0.62CVX Chevron CorpPairCorr

Related Correlations Analysis

Click cells to compare fundamentals   Check Volatility   Backtest Portfolio

Risk-Adjusted Indicators

There is a big difference between Gilead Stock performing well and Gilead Sciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Gilead Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Gilead Sciences Corporate Management

Mr MDVP DevelopmentProfile
SeeChun MDVP OncologyProfile
Monica TijerinaClinical ManufacturingProfile
Janet DorlingSenior SolutionsProfile
Johanna MercierChief Commercial OfficerProfile
Bilal PiperdiVice OncologyProfile